Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott (ABT) Stock Moves -1.02%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $88.71, moving -1.02% from the previous trading session.
Coronavirus Diagnostic Tests in High Demand: 4 Stocks in Focus
by Debanjana Dey
Amid the pandemic, these four companies with strong diagnostics testing developments might show better resilience.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $90.28 in the latest trading session, marking a -0.68% move from the prior day.
3 MedTech Stocks to Watch Amid Coronavirus Catastrophe
by Trina Mukherjee
Let's keep a watch on three stocks that have displayed strong performance amid market turmoil led by the ongoing pandemic.
Abbott's Libre 2 iCGM Gets FDA Nod to Better Manage Diabetes
by Zacks Equity Research
Abbott's (ABT) FDA-cleared FreeStyle Libre 2 iCGM is the only available system to continuously transmit glucose data with real-time alarms.
Abbott's (ABT) FreeStyle Libre Study Outcome Favorable
by Zacks Equity Research
The latest study outcome aligns with the American Diabetes Association's recommended A1c level of 7% for adults with diabetes.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $89.02, marking a +1.41% move from the previous day.
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments
Diagnostic Testing Remains Crucial in Combatting Coronavirus
by Trina Mukherjee
Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.
Danaher's (DHR) Product Offerings to Aid Amid Pandemic Scares
by Zacks Equity Research
Danaher's (DHR) risks from pandemic-related uncertainties are evident from weak sales projections for the second quarter. Demand for acute care diagnostics' related products might aid results.
Abbott Stock Down on Urgent Field Safety Notice for TactiCath
by Zacks Equity Research
Abbott (ABT) also mentions certain guidelines related to product return, reporting, and customer assistance.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $92.62 in the latest trading session, marking a -0.42% move from the prior day.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $90.76 in the latest trading session, marking a +1.43% move from the prior day.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $90.39, marking a +0.33% move from the previous day.
Why Is Abbott (ABT) Down 6.4% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Healthcare Tech & Robotics ETFs in Focus amid COVID-19 Crisis
by Neena Mishra
The pandemic will forever transform our lives; here are some areas that may benefit.
BJ's Wholesale Club, Polaris Industries, Abbott Laboratories, Eldorado Resorts and Apple highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
BJ's Wholesale Club, Polaris Industries, Abbott Laboratories, Eldorado Resorts and Apple highlighted as Zacks Bull and Bear of the Day
3 Medical Product Stocks Set to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on several factors.
Biotech ETFs Poised to Benefit From Coronavirus
by Neena Mishra
Rising investor interest in coronavirus related stocks will benefit these ETFs
HRC vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRC vs. ABT: Which Stock Is the Better Value Option?
3 Stocks Set to Pop Once the Economy Gets Back to Business
by Tirthankar Chakraborty
We have highlighted three stocks will flourish when the economy reopens. Notably, an increasing number of states are expected to reopen their economies in the first two weeks of May.
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
Top Stock Research Reports for Cisco, Abbott, NextEra & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.